Company Overview of Epizyme, Inc.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase II clinical trial of tazemetostat (EPZ-6438), an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and INI1-deficient solid tumors; and two Phase I clinical trials of pinometostat (EPZ-5676), an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with geneti...
400 Technology Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Epizyme, Inc.
Chief Scientific Officer and President of Research
Total Annual Compensation: $531.7K
Chief Medical Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.
Epizyme, Inc. Key Developments
Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA
Feb 8 16
Epizyme, Inc. announced that the United States Food and Drug Administration (FDA) has granted orphan drug status to the company’s first-in-class EZH2 inhibitor, tazemetostat, for the treatment of malignant rhabdoid tumors (MRTs). In December 2015, the company initiated a phase 2 study in adults and a phase 1 study in children with genetically defined tumors, including MRTs. Tazemetostat is also being investigated in an ongoing five-arm phase 2 study in patients with non-Hodgkin lymphoma. Orphan drug designation provides the sponsor of the drug with eligibility for various development incentives, including tax credits for qualified clinical testing and marketing exclusivity for a period of seven years. Therapies with orphan drug status are also not subject to a prescription drug user fee for the orphan indication. Currently, treatment of MRT consists of surgery, chemotherapy and radiation therapy, which are associated with limited efficacy and significant treatment-related morbidity. MRT is a tumor defined by loss of INI1 protein as measured by immunohistochemistry. Other rhabdoid tumors, such as MRT of ovary, are characterized by loss of the protein SMARCA4 and have shown sensitivity to tazemetostat in preclinical models and in the phase 1 study. The orphan drug designation applies to both INI1-negative MRT as well as SMARCA4-negative MRT of ovary. The ongoing phase 2 adult and phase 1 pediatric studies in patients with genetically-defined solid tumors include patients with rhabdoid tumors, other INI1-negative tumors, and synovial sarcoma. Interim data from Epizyme’s registration-supporting phase 2 clinical study of tazemetostat in adult patients with genetically defined solid tumors, including MRT, other INI1-negative tumors and synovial sarcoma, are anticipated to be presented at a medical conference in late 2016.
Epizyme, Inc. Presents at Canaccord Genuity Rare Disease and BioPharma 1x1 Day, Feb-02-2016
Feb 1 16
Epizyme, Inc. Presents at Canaccord Genuity Rare Disease and BioPharma 1x1 Day, Feb-02-2016 . Venue: Omni Berkshire Place, New York, New York, United States.
Epizyme, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM
Jan 19 16
Epizyme, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:05 AM. Venue: The Waldorf Astoria, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|